

## FRIDAY, 6 September – Pre-conference Education Course

9:00 AM Walk in coffee

9:30 AM Parallel sessions - Integrated training on:

- **Basic colonoscopy**  
**Manar Salah**, Ain Shams University, Egypt
- **Basic upper endoscopy**  
**Ahmed Talaat Elganzory**, Ain Shams University, Egypt
  
- **Point of care testing**  
**Elena Ivanova Reipold**, FIND, Switzerland;  
**Cynthia Tamandjou**, University of Cape Town, South Africa;  
**Shivraj Bhoite**, Molbio Diagnostics, India;  
**Marc Amphlett**, Genedrive, United Kingdom

11:30 AM Program break - Friday afternoon prayer

1:00 PM Lunch

**2:00 PM Opening of the conference**  
*Chairs: Manal El-Sayed, MD, PhD*

2:15 PM **Keynote lecture: Global efforts on viral hepatitis elimination**  
**John Ward, MD**  
Centers for Disease Control, USA

2:45 PM **What's new in viral hepatitis - including EASL coverage**  
**Thomas Berg, MD**  
University Hospital Leipzig, Germany

3:15 PM **Viral hepatitis and pregnancy**  
**Wendy Spearman, MD, PhD**  
University of Cape Town, South Africa

3:45 PM **Discussion**

4:00 PM Break

**Session 1 HCC and its management**  
*Chairs: Olufunmilayo Lesi, FWACP, FMCP*

4:30 PM **Epidemiology, burden of disease and outcomes of HCC in Africa**  
**Edith Okeke, MD**  
University of Jos, Nigeria

4:55 PM **Improving risk stratification and early detection of HCC in Africa**  
**Ashraf Omar, MD**  
Cairo University, Egypt

5:20 PM **Surgical therapy for HCC – including resection and liver transplantation**  
**Mahmoud El-Meteini, MD, M.B.B.ch**  
Ain Shams University, Egypt



5:45 PM **Loco-regional therapy for HCC – including ablation, chemoembolization and hepatic artery embolization**

**Benjamin Sarkodie, MD**

University of Ghana School of Medicine & Dentistry, Ghana

6:10 PM **Systemic therapy – what is realistic in the LMIC setting?**

**Mitesh Borad, MD**

Mayo Clinic Arizona, USA

6:35 PM **Needs for research and advocacy for HCC in Africa**

**Olufunmilayo Lesi, FWACP, FMCP**

WHO Regional Office for Africa, Congo

### Discussion

7:00 PM Welcome reception

## SATURDAY, 7 September

8:00 AM **Industry Supported Symposium I - Gilead: SOF/VEL/VOX. Current position in HCV management in today's guidelines**

### Session 2 Management of viral hepatitis (I) - HBV related

*Chairs: Wendy Spearman MD, PhD & Thomas Berg, MD*

9:00 AM **Simplification of HBV treatment algorithm**

**Ayman Yosry, MD**

Cairo University, Egypt

9:25 AM **Treatment of HBV in sub-Saharan Africa**

**Hailemichael Desalegn, MD**

St. Paul's Hospital Millennium Medical College, Ethiopia

### Abstract-driven presentations:

9:50 AM	Prevalence of Hepatitis B Surface Antigen (HBsAg) positivity and its associated factors in Rwanda/risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program	Jean Damascene Makuza	#01-A /#01-B
---------	---	-----------------------	-----------------

10:00 AM	Prenatal consultation as a starting point for family screening of hepatitis B virus, the CI cohort ANRS 12359	Nanelin Alice Guingane	#02
----------	---	------------------------	-----

10:10 AM	Analysis of the National Hepatitis B Viral Load Testing Programme in Uganda	Viola Kasone	#03
----------	---	--------------	-----

10:20 AM	High rates of HBV functional cure among HIV/HBV-coinfected patients on ART in Zambia	Michael Vinikoor	#04
----------	--	------------------	-----

10:30 AM Break



---

## Session 3 Management of viral hepatitis (III) - HCV related

*Chairs: Mark Nelson, MD, FRCP & Mary Afihene MBChB, FWACP*

---

11:00 AM **Treatment of hepatitis C in SSA (Rwanda)**

**Neil Gupta, MD**

Harvard Medical School, USA

11:25 AM **Hepatitis delta**

**Mario Rizetto, MD**

University of Torino, Italy

### Abstract-driven presentations:

11:50 PM	Hepatitis C treatment among people who inject drugs in Kenya: preliminary findings of the test and link to care for injecting drug users study C infection in Rwanda: results from a nationwide screening program	Mercy Nyakowa	#05
----------	---	---------------	-----

12:00 PM	Efficacy of Direct-Acting Antiviral (DAA) regimens in HIV/HCV-co-infected patients in Libya	Nagat Bousifi	#06
----------	---	---------------	-----

12:10 PM	Assessment of liver fibrosis after Direct-Acting Antiviral therapy in compensated and decompensated HCV-related liver diseases	Mohammed Mohammed	#07
----------	--	-------------------	-----

12:20 PM	Heading toward hepatitis C virus elimination: Tunisian experience, achievements and prospects	Mouna Safer	#08
----------	---	-------------	-----

12:30 PM Lunch

### Get your paper published in The Lancet

**1:15 PM Robert Brierley**

The Lancet Gastroenterology & Hepatology, United Kingdom

### HBV Cure Science 101 - organized by ICE-HBV

**1:45 PM Anna Kramvis, BScHons, PhD**

International Coalition to Eliminate HBV (ICE-HBV) / University of the Witwatersrand, South Africa

---

## Session 4 Public health - Egypt's model of care

*Chairs: Gamal Esmat, MD & John Ward, MD*

---

2:45 PM **Screening of 50 million people**

**Manal El-Sayed, MD, PhD**

Ain Shams University, Egypt

3:05 PM **Scaling up treatment**

**Wahid Doss, MD**

Cairo University, Egypt



- 3:25 PM **Round Table discussion: Translation of Egypt's experience to the rest of Africa**  
**Wahid Doss, MD** - Cairo University, Egypt  
**Gamal Esmat, MD** - Cairo University, Egypt  
**Magdy El-Serafy, MD** - Cairo University, Egypt  
**Imam Waked, MB, BCh, MSc, MD, FAASLD** - National Liver Institute, Egypt  
**Mohamed Hassany, MD** - National Hepatology and Tropical Medicine Research Institute, Egypt  
**Jean Damascene Makuza, MD** - Rwanda Biomedical Center, Rwanda

4:10 PM Break

## Session 5 Civil society contribution in Africa - organized by World Hepatitis Alliance

*Chairs: Cary James & Gamal Shiha, MD, MBBH, MSc*

- 4:40 PM **Round table Discussion: the role of patient support groups**  
**Cary James** - World Hepatitis Alliance, United Kingdom  
**Bisi Bright** - LiveWell Initiative LWI, Nigeria  
**Mohamed El-Wahsh** - Tanya Masr, Egypt  
**Ammal Metwally, MD, PhD** - National Research Center, Egypt  
**Coulibaly Alioune Badara, MD** - Association pour la Promotion de la Sante et le Developpement (APSAD), Mali  
**Kenneth Kabagambe, BA** - The National Organisation for People Living with Hepatitis B (NOPLHB), Uganda  
**Elodie Sanasee** - Prévention Information et Lutte contre le SIDA (PILS), Mauritius

## SUNDAY, 8 September

### 8:00 AM Industry Supported Symposium II: Economic impact and funding for hepatitis elimination - drawing from Egypt's success

#### Session 6 NASH/NAFLD management in Africa

*Chairs: John Rwegasha MBChB, M.MED, FRCP, MSc & Imam Waked, MB, BCh, MSc, MD, FAASLD*

#### 9:00 AM New therapies for NASH/NAFLD

**Thomas Berg, MD**  
University Hospital Leipzig, Germany

#### 9:30 AM Clinical case presentation

**Imam Waked, MB, BCh, MSc, MD, FAASLD**  
National Liver Institute, Egypt

#### Abstract - driven presentations:

- |          |  |                    |     |
|----------|--|--------------------|-----|
| 10:00 AM | HCC developed following DAAs treatment does not display more aggressive pattern  | Gamal Shiha        | #09 |
| 10:10 AM | Factors associated with liver toxicity among HIV infected children and adolescents attending a national referral pediatric HIV clinic in Uganda  | Bonny Mulindwa     | #10 |
| 10:20 AM | Prevalence of fatty liver disease and associated factors among outpatients attending internal medicine clinics at Muhimbili University of Health and Allied Sciences Academic Medical Centre, Tanzania | Nontobeko Simelane | #11 |

#### 10:30 AM Best of Posters

*Chairs: Mark Nelson, MD, FRCP & Manal El-Sayed, MD, PhD*



11:00 AM Break

**11:30 AM Industry Supported Symposium III - Pharco:  
Innovation of access to treatment: Real Life Scenarios**

1:00 PM Lunch

---

## **Session 7 WHO sponsored session on viral hepatitis and universal health coverage**

---

2:00 PM **The global and regional hepatitis elimination agenda**

**Joumana Hermez**

WHO/EMRO, Egypt

2:10 PM **Access to hepatitis B and C medicines**

**Morgane Ahmar**

International Treatment Preparedness Coalition (ITPC), Morocco

2:20 PM **Leaving no one behind: role of civil society in reaching people who inject drugs (PWID) for hepatitis elimination**

**Elie Aaraj**

Middle East and North Africa Harm Reduction Association (MENAHRRA), Lebanon

2:30 PM **Innovative financing and financial protection: inclusion of viral hepatitis services**

**Awad Mataria, PhD**

WHO/EMRO, Egypt

2:40 PM **Fitting viral hepatitis elimination in the UHC agenda**

**Awad Mataria, PhD**

WHO/EMRO, Egypt

2:45 PM **Discussion**

---

### **Closure of the conference**

---

3:30 PM **Conference Summary and Conclusions from the Conference Co-Chairs**

**Manal El-Sayed & Charles Boucher**

Ain Shams University, Egypt & Erasmus Medical Center, the Netherlands

3:50 PM **President of Ain Shams University speech**

**Mahmoud El-Meteini**

Ain Shams University, Egypt

4:00 PM **Minister of Health speech**

**Her Excellency Dr. Hala Zayed**

Ministry of Health, Egypt

4:10 PM **Minister of Investment and International Cooperation speech**

**Her Excellency Dr. Sahar Nasr**

Ministry of Investment and International Cooperation, Egypt

4:20 PM **Minister of Higher Education speech**

**His Excellency Prof. Khaled Abdel-Ghaffar**

Ministry of Higher Education, Egypt

4:30 PM **Closure of the conference**

